)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Poxel
Poxel (POXEL) investor relations material
Poxel Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary19 Oct, 2026
Executive summary
Q3 2026 consolidated revenue was €1,951k; 9M revenue reached €4,453k, driven by TWYMEEG royalties in Japan.
TWYMEEG net sales exceeded the JPY 5bn threshold in Sumitomo Pharma FY2026 H1, raising the royalty rate from 8% to 10% retroactively for FY2026.
Financial highlights
Q3 revenue was €1,951k vs €1,292k in Q3 2025; 9M revenue was €4,453k vs €3,608k in 9M 2025.
Q3 revenue included €1,629k in royalties and a €322k retroactive Q2 royalty adjustment; 9M included €4,131k in royalties and €322k in adjustments.
Consolidated cash and cash equivalents were €388k at September 30, 2026, vs €1,510k at Q2 2026 and €245k at Q1 2026.
Outlook and guidance
Sumitomo Pharma expects FY2026 TWYMEEG net sales to exceed JPY 10bn; the milestone would trigger a JPY 1bn bonus and increase royalties from 10% to 12%.
Based on Sumitomo Pharma projections, 12% royalties are expected on TWYMEEG Japan net sales during its FY2026, which runs April 2026–March 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Poxel
- OrbiMed royalty monetization extends runway while rare-disease and Imeglimin partnering advance.POXEL
Corporate presentation - Revenue up to EUR 6.6m in 2024, but reorganization and going concern risks remain.POXELH2 2024
- Advancing rare metabolic disease therapies with strong clinical assets and strategic partnerships.POXELCorporate presentation
- TWYMEEG® sales growth and asset divestment drive revenue, with financial reporting delayed.POXELQ2 2026 TU
- TWYMEEGⓇ sales surged 36% in Japan, boosting royalties and revenue for Q1 2026.POXELQ1 2026
- Revenue up 88% and net loss reduced amid receivership and recovery plan implementation.POXELH1 2025
- 2024 revenue up, net loss down, and judicial reorganization underway with new financing.POXELQ3 2025
- Cash runway limited to Q1 2025, with future dependent on February 2025 shareholder vote.POXELH1 2024
- TWYMEEG® sales growth and strengthened cash position extend Poxel's runway through 2025.POXELQ3 2024 TU
Next Poxel earnings date
H1 202620 Nov, 2026
Poxel
Next Poxel earnings date
H1 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Poxel S.A. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases, particularly those related to metabolic disorders. The company's research pipeline includes treatments for conditions like non-alcoholic steatohepatitis (NASH) and rare metabolic diseases such as adrenoleukodystrophy (ALD). Poxel leverages proprietary platforms including adenosine monophosphate-activated protein kinase (AMPK) activators and deuterated thiazolidinedione (TZD) compounds. The company is headquartered in Lyon, France, with additional offices in Boston, Massachusetts, and Tokyo, Japan. Its shares are listed on Euronext Paris.